Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05945823 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | active not recruiting | Phase 2 | 53 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 1, 2026 | clinicaltrials |
| NCT07796594 | Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer(SONATA) | active not recruiting | N/A | 180 | Amsterdam UMC, location VUmcOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07796997 | GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy | not yet recruiting | Phase 1 | 20 | University of Illinois at ChicagoOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03652428 | Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) | active not recruiting | Phase 1 / Phase 2 | 24 | University of Maryland, BaltimoreOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05497531 | Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers | recruiting | N/A | 15 | University of California, IrvineOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06084013 | Use Of Indocyanine Green In Pancreas Surgery | recruiting | — | 55 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07736612 | A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 80 | Zhejiang UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07794969 | Pancreatic Cancer Lifestyle Evolution And Resistance(CLEAR) | not yet recruiting | — | 150 | IRCCS San RaffaeleOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | not yet recruiting | Early Phase 1 | 40 | Lumina Pharmaceuticals IncINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07791550 | Baduanjin for Quality of Life in Pancreatic Cancer Chemotherapy(BDJ-PC) | not yet recruiting | N/A | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02892305 | Hepatic Resection for Metastatic Pancreatic Cancer | active not recruiting | — | 18 | Duke UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | recruiting | Phase 1 | 100 | Nammi Therapeutics IncINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06698458 | Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer | recruiting | N/A | 50 | Alpha Tau Medical LTD.INDUSTRY | 3 | Aug 27, 2026 | clinicaltrials |
| NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | recruiting | Phase 1 | 200 | Sutro Biopharma, Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07630961 | Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07640295 | Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations | recruiting | Phase 1 / Phase 2 | 80 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04157127 | Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma(DECIST) | recruiting | Phase 1 | 18 | Diakonos Oncology CorporationINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06313970 | First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients | active not recruiting | Phase 2 | 58 | Fudan UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06885697 | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | recruiting | Phase 1 | 100 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06893276 | e-Health Psychosocial Stress and Symptom Management (ePSMI) for Pancreatic Cancer Patients | recruiting | N/A | 60 | University of MiamiOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06938282 | An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer | recruiting | Phase 2 | 60 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07494994 | SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent(SURGIMEDIA) | not yet recruiting | N/A | 60 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787156 | Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial(REGENERATE) | not yet recruiting | N/A | 80 | Brigham and Women's HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06958328 | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer(LAP100) | recruiting | Phase 3 | 356 | NRG OncologyOTHER | 2 | Aug 25, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784374 | A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation | not yet recruiting | Phase 2 | 120 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03190941 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | recruiting | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05517811 | Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection(TEG) | recruiting | — | 200 | University of Colorado, DenverOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06586515 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01) | recruiting | Phase 1 | 630 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 199 | National Cancer Institute (NCI)NIH | 2 | Aug 21, 2026 | clinicaltrials |
| NCT06843551 | The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation(EMPIRE) | recruiting | Phase 2 | 20 | Benjamin SpielerOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | active not recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07274657 | Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy(SMILE) | recruiting | N/A | 150 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07608458 | Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy | not yet recruiting | N/A | 70 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07619313 | AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | recruiting | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07776353 | Understanding New Cachexia Subtypes Through Observational Epidemiological Research(UNCOVER) | recruiting | — | 800 | Kaiser PermanenteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777211 | A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03454035 | Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | recruiting | Phase 1 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05692323 | A Supervised Prehabilitation Program for Patients With Pancreatic Cancer(PREHAB) | active not recruiting | N/A | 16 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07175389 | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07226154 | Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer(PRECEPT) | recruiting | — | 200 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07772258 | Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer(POWR-PaC) | not yet recruiting | N/A | 120 | Manchester University NHS Foundation TrustOTHER_GOV | 0 | Aug 19, 2026 | clinicaltrials |
| NCT07773363 | Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer | not yet recruiting | Phase 2 | 37 | Tang-Du HospitalOTHER | 0 | Aug 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 1, 2026source: clinicaltrials